You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children

Cox, Charles S Jr MD*; Baumgartner, James E MD*; Harting, Matthew T MD*†; Worth, Laura L MD, PhD§; Walker, Peter A MD*†; Shah, Shinil K DO*†; Ewing-Cobbs, Linda PhD*; Hasan, Khader M PhD‡; Day, Mary-Clare RN, BSN*; Lee, Dean MD, PhD§; Jimenez, Fernando MS*; Gee, Adrian PhD¶

doi: 10.1227/NEU.0b013e318207734c
Research-Human-Clinical Studies
Press Release

BACKGROUND: Severe traumatic brain injury (TBI) in children is associated with substantial long-term morbidity and mortality. Currently, there are no successful neuroprotective/neuroreparative treatments for TBI. Numerous preclinical studies suggest that bone marrow-derived mononuclear cells (BMMNCs), their derivative cells (marrow stromal cells), or similar cells (umbilical cord blood cells) offer neuroprotection.

OBJECTIVE: To determine whether autologous BMMNCs are a safe treatment for severe TBI in children.

METHODS: Ten children aged 5 to 14 years with a postresuscitation Glasgow Coma Scale of 5 to 8 were treated with 6 × 106 autologous BMMNCs/kg body weight delivered intravenously within 48 hours after TBI. To determine the safety of the procedure, systemic and cerebral hemodynamics were monitored during bone marrow harvest; infusion-related toxicity was determined by pediatric logistic organ dysfunction (PELOD) scores, hepatic enzymes, Murray lung injury scores, and renal function. Conventional magnetic resonance imaging (cMRI) data were obtained at 1 and 6 months postinjury, as were neuropsychological and functional outcome measures.

RESULTS: All patients survived. There were no episodes of harvest-related depression of systemic or cerebral hemodynamics. There was no detectable infusion-related toxicity as determined by PELOD score, hepatic enzymes, Murray lung injury scores, or renal function. cMRI imaging comparing gray matter, white matter, and CSF volumes showed no reduction from 1 to 6 months postinjury. Dichotomized Glasgow Outcome Score at 6 months showed 70% with good outcomes and 30% with moderate to severe disability.

CONCLUSION: Bone marrow harvest and intravenous mononuclear cell infusion as treatment for severe TBI in children is logistically feasible and safe.

Author Information

*Departments of Pediatric Surgery, †Surgery, and ‡Diagnostic & Interventional Imaging, University of Texas Medical School at Houston, Houston, Texas; Children's Memorial Hermann Hospital, University of Texas, Houston, Texas; §Department of Pediatrics, Division of Cell Therapy, MD Anderson Cancer Center, Houston, Texas; ¶Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas

Received, December 18, 2009.

Accepted, May 6, 2010.

Correspondence: Charles S. Cox Jr, MD, 6431 Fannin, MSB 5.236, Houston, TX 77030. E-mail:

Copyright © by the Congress of Neurological Surgeons